Home - Products - Polypeptide
Mobile/Wechat/WhatsApp: +852 61915425
Email:niki@healthtide-api.com
CasNo: 16960-16-0
Molecular Formula: C136H210N40O31S
Description |
Cosyntropin, also known as Cortrosyn, is a synthetic derivative of adrenocorticotropic hormone (ACTH) used in the evaluation and diagnosis of patients with adrenocortical insufficiency. It is a man-made portion of a natural substance produced by the body, ACTH, and is available in generic form. |
Chemical Properties |
White or yellow, amorphous powder. |
Uses |
Cosyntropin is administered via intramuscular injection or direct intravenous injection as part of a medical test called an ACTH stimulation test. This test assesses adrenal gland function by measuring the adrenal response to ACTH stimulation. Additionally, cosyntropin may be given as an intravenous infusion over several hours to provide a more robust stimulus to the adrenal glands. As a synthetic peptide consisting of the first 24 amino acids of corticotropin, cosyntropin offers advantages over naturally occurring hormone in terms of longer duration of action and lacking the antigenic portion of corticotropin. While the short cosyntropin test is a recognized screening test for assessing adrenocortical insufficiency, other tests such as the overnight metyrapone test or insulin hypoglycemia test may be more sensitive in certain cases. |
Clinic uses | Cosyntropin plays a vital role in diagnosing adrenal gland problems including Addison's disease, insufficiency due to corticosteroid use, and pituitary tumors, thus aiding in the evaluation and management of patients with adrenocortical insufficiency. |
InChI:InChI=1/C136H210N40O31S/c1-75(2)109(127(200)154-71-106(181)156-88(31-13-17-52-137)114(187)158-89(32-14-18-53-138)115(188)159-91(35-21-56-149-134(142)143)116(189)164-96(37-23-58-151-136(146)147)131(204)175-60-25-39-104(175)126(199)173-111(77(5)6)128(201)163-90(33-15-19-54-139)120(193)171-110(76(3)4)129(202)169-101(65-80-43-47-84(180)48-44-80)132(205)176-61-26-40-105(176)133(206)207)172-125(198)103-38-24-59-174(103)130(203)95(34-16-20-55-140)157-107(182)70-153-113(186)99(66-81-68-152-87-30-12-11-29-85(81)87)167-117(190)92(36-22-57-150-135(144)145)160-121(194)98(63-78-27-9-8-10-28-78)166-123(196)100(67-82-69-148-74-155-82)168-118(191)93(49-50-108(183)184)161-119(192)94(51-62-208-7)162-124(197)102(73-178)170-122(195)97(165-112(185)86(141)72-177)64-79-41-45-83(179)46-42-79/h8-12,27-30,41-48,68-69,74-77,86,88-105,109-111,152,177-180H,13-26,31-40,49-67,70-73,137-141H2,1-7H3,(H,148,155)(H,153,186)(H,154,200)(H,156,181)(H,157,182)(H,158,187)(H,159,188)(H,160,194)(H,161,192)(H,162,197)(H,163,201)(H,164,189)(H,165,185)(
Available diagnostic studies include the insulin tolerance test (ITT), the cosyntropin stimulation test (CST) with use of 1 μg or 250 μg of cosyntropin, and the metyrapone test (which is no longer available in the United States). The current “gold standard” test is the ITT, but it can be difficult to perform and
LC-MS/MS provides cutoff levels for cortisol and 17-OHP after cosyntropin stimulation that are lower than those based on immunoassays, possibly because cross-reactivity between steroid intermediates and cortisol is eliminated. This reduces the number of false-positive tests for AI and false-negative tests for NCCAH.